The US Food and Drug Administration needs more tailored enforcement authority to streamline opioid Risk Evaluation and Mitigation Strategy administration, a federal watchdog argued.
A review of the FDA’s handling of the REMS for extended-release-long-acting opioid and transmucosal immediate-release fentanyl (TIRF) products by the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?